True. I think they want considerably more than $1 million upfront to really get things moving on Kevetrin, additional Brilacidin indications, and to relieve the balance sheet/funding pressure so the stock can really escape orbit.
I guess the upside to not having a lot of comparable drugs is all that blue sky!
News 
Market Data 
Discover 
